Cite
HARVARD Citation
Loubière, S. et al. (2018). Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. European respiratory journal. 51 (3), p. . [Online].